High-Yield Urology 2026: A Guideline-Based Review • Author @BenDropkin • Book https://xitter.cf/t.co/uc5GwDuFzO • Q Bank https://xitter.cf/t.co/oYQ9dxE128
Joined May 2021
- Tweets264
- Following4.8K
- Followers2.5K
- Likes82
Pinned Tweet
🚨🚨🚨 @HighYieldUro Q BANK is Now Live!
🚀 1500+ high-yield questions built for in-service and board exam prep
👉 get started: qbank.com/hyu
💸 group discount info: highyieldurology.com/pages/q…
👇 preview & example question below
@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
🤖 Made with AI
🚨T-minus 4️⃣ weeks to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ prepare to ace your exam with @HighYieldUro 2026 📖 and Q-Bank 💻📱
🚨🚨🚨 @HighYieldUro Q BANK is Now Live!
🚀 1500+ high-yield questions built for in-service and board exam prep
👉 get started: qbank.com/hyu
💸 group discount info: highyieldurology.com/pages/q…
👇 preview & example question below
@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
High-Yield Urology retweeted
Presented at #ESMO26:
In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm
@myESMO
ALT A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).
🚨T-minus 5️⃣ weeks to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ prepare to ace your exam with @HighYieldUro 2026 📖 and Q-Bank 💻📱
highyieldurology.com/
High-Yield Urology retweeted
JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1
@ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert
Outstanding work, @urogabe 👏
High-Yield Urology retweeted
❓ What's new in the 2026 AUA/SUO NMIBC Guideline?
Last week, we released an amendment to the Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Guideline.
In this brief video, guideline panel member Dr. Jeff Holzbeierlein highlights key updates, including revised risk classification and new treatment recommendations designed to help clinicians navigate the rapidly evolving non-muscle invasive bladder cancer treatment landscape.
🔗 Check out the guideline now: bit.ly/4xxuZHj
1️⃣1️⃣ weeks to go until the @AmerUrological In-Service Exam ⏳
🚨🚨🚨 @HighYieldUro Q BANK is Now Live!
🚀 1500+ high-yield questions built for in-service and board exam prep
👉 get started: qbank.com/hyu
💸 group discount info: highyieldurology.com/pages/q…
👇 preview & example question below
@uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2026 📖🚀 highyieldurology.com/
🚨KEYNOTE-B15/EV-304 @NEJM
🌎🌍🌏 808 pts w/ untreated cisplatin-eligible, cystectomy-eligible MIBC ➡️ perioperative enfortumab vedotin (ADC to Nectin-4) + pembro (PD-1🛑) vs. neoadjuvant gem/cis ➡️ cystectomy ➡️ 2yr EFS 79% vs 66% (P<.001), 2yr OS 87% vs 81% (P=.006), pCR 56% vs 33% (P<.001) ➡️ ⬆️G3+ AEs (76% vs 67%) ➡️ FDA-approved ✅
nejm.org/doi/full/10.1056/NE…
